2463 related articles for article (PubMed ID: 8065154)
1. Nude mouse model to study passive humoral immunotherapy directed against B16 F10 murine melanoma.
Shrayer D; Bogaars H; Gersten D; Hearing V; Maizel A; Wanebo H
J Surg Oncol; 1994 Sep; 57(1):50-6. PubMed ID: 8065154
[TBL] [Abstract][Full Text] [Related]
2. Preimmunization of mice with formalinized extracellular antigens of melanoma in combination with IL-2 and surgical resection increased survival and tumor control in metastatic melanoma model.
Shrayer D; Koness J; Kouttab N; Bogaars H; Hearing VJ; Gersten DM; Maizel A; Wanebo H
J Surg Oncol; 1993 Mar; 52(3):142-9. PubMed ID: 8441268
[TBL] [Abstract][Full Text] [Related]
3. Generation of cytotoxic antibodies to the B16 murine melanoma using a formalinized vaccine.
Shrayer D; Kouttab N; Maizel A; Wanebo H; Hearing VJ; Gersten DM
Int J Cancer; 1993 Feb; 53(4):696-702. PubMed ID: 8436442
[TBL] [Abstract][Full Text] [Related]
4. Induction of interleukin-2, natural killer cell activity and anti-melanoma antibodies resulting from immunization of mice with formalinized extracellular antigens (FECA) of murine melanoma.
Shrayer D; Koness J; Maizel A; Wanebo H
Melanoma Res; 1992 May; 2(1):47-56. PubMed ID: 1643424
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the growth of human melanoma metastases in nude mice by melanoma-specific murine monoclonal antibody.
Abdel-Wahab ZA; Darrow TL; Vervaert CE; Giannopoulou AA; Li W; Seigler HF
Surg Oncol; 1992 Apr; 1(2):115-25. PubMed ID: 1341242
[TBL] [Abstract][Full Text] [Related]
6. A new mouse model of experimental melanoma for vaccine and lymphokine therapy.
Shrayer DP; Bogaars H; Wolf SF; Hearing VJ; Wanebo HJ
Int J Oncol; 1998 Aug; 13(2):361-74. PubMed ID: 9664134
[TBL] [Abstract][Full Text] [Related]
7. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma.
Lucas ML; Heller L; Coppola D; Heller R
Mol Ther; 2002 Jun; 5(6):668-75. PubMed ID: 12027550
[TBL] [Abstract][Full Text] [Related]
8. Serological characterization of a shared melanoma-associated antigen of mouse melanomas: relationship to the B700 glycoprotein.
DeLeo AB; Hearing VJ; Vieira WD; Law LW
Melanoma Res; 1991; 1(2):133-40. PubMed ID: 1668533
[TBL] [Abstract][Full Text] [Related]
9. Immunization of mice with irradiated melanoma tumor cells transfected to secrete lymphokines and coupled with IL-2 or GM-CSF therapy.
Shrayer DP; Bogaars H; Hearing VJ; Wanebo HJ
J Exp Ther Oncol; 1996 Mar; 1(2):126-33. PubMed ID: 9414396
[TBL] [Abstract][Full Text] [Related]
10. Further characterization of a clinically relevant model of melanoma metastasis and an effective vaccine.
Shrayer D; Bogaars H; Hearing VJ; Maizel A; Wanebo H
Cancer Immunol Immunother; 1995 May; 40(5):277-82. PubMed ID: 7600558
[TBL] [Abstract][Full Text] [Related]
11. The role of monoclonal antibody affinity in tumor immunotherapy evaluated in in vivo models for minimal residual disease.
Velders MP; van Rhijn CM; Cornelissen IM; van Muijen GN; Briaire IH; Dohlsten M; Fleuren GJ; Warnaar SO; Litvinov SV
J Immunother Emphasis Tumor Immunol; 1996 Jul; 19(4):245-56. PubMed ID: 8877719
[TBL] [Abstract][Full Text] [Related]
12. Further studies of the therapeutic effects of murine melanoma-specific monoclonal antibodies.
Law LW; Vieira WD; Hearing VJ; Gersten DM
Biochim Biophys Acta; 1994 Apr; 1226(1):105-9. PubMed ID: 7908833
[TBL] [Abstract][Full Text] [Related]
13. Suppression of B16 melanoma lung colonization by syngeneic monoclonal antibodies.
Herd ZL
Cancer Res; 1987 May; 47(10):2696-703. PubMed ID: 3552203
[TBL] [Abstract][Full Text] [Related]
14. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
[TBL] [Abstract][Full Text] [Related]
15. Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1.
Khokha R
J Natl Cancer Inst; 1994 Feb; 86(4):299-304. PubMed ID: 8158685
[TBL] [Abstract][Full Text] [Related]
16. Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-alpha and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody.
Eisenthal A; Cameron RB; Rosenberg SA
J Immunol; 1990 Jun; 144(11):4463-71. PubMed ID: 2111349
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of tumor cell vaccine after incorporating monophosphoryl lipid A (MPL) in tumor cell membranes containing tumor-associated ganglioside.
Ravindranath MH; Brazeau SM; Morton DL
Experientia; 1994 Jul; 50(7):648-53. PubMed ID: 8033972
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor activity of class II MHC antigen-restricted cloned autoreactive T cells. II. Novel immunotherapy of B16 melanomas by local and systemic adoptive transfer.
Shiohara T; Moellmann G; Jacobson K; Kuklinska E; Ruddle NH; Lerner AB
J Immunol; 1987 Mar; 138(6):1979-86. PubMed ID: 3493292
[TBL] [Abstract][Full Text] [Related]
19. Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma.
Hirschowitz EA; Leonard S; Song W; Ferris B; Leopold PL; Lewis JJ; Bowne WB; Wang S; Houghton AN; Crystal RG
Gene Ther; 1998 Jul; 5(7):975-83. PubMed ID: 9813669
[TBL] [Abstract][Full Text] [Related]
20. A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo.
Carr A; Mazorra Z; Alonso DF; Mesa C; Valiente O; Gomez DE; Perez R; Fernandez LE
Melanoma Res; 2001 Jun; 11(3):219-27. PubMed ID: 11468510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
